Article

Novel Dual Inhibitors of PARP and HDAC Induce Intratumoral STING-Mediated Antitumor Immunity in Triple-Negative Breast Cancer

2023-01-14

Abstract excerpt

<h4>Background: </h4> and Purpose: PARP and HDAC inhibitors are approved for the clinical treatment of malignancies, but acquired resistance or limited effects on solid tumors with single-agent present challenges. Therefore, there is an urgent need to design and synthesis of dual inhibitors involving a different mechanism of action can provide new treatments. Experimental Approach: We validate the correlation and...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0aa22cf6-6d4d-5b7a-b008-3fa227d9cd7d
DOI: 10.22541/au.167369414.48398608/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Novel Dual Inhibitors of PARP and HDAC Induce Intratumoral STING-Mediated Antitumor Immunity in Triple-Negative Breast CancerDOI 10.22541/au.167369414.48398608/v1Read

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast CancerSemantic proximity Read

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationSemantic proximity Read

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.Semantic proximity Read

Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathwaySemantic proximity Read

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsSemantic proximity Read

The Synergistic Effect of PARP Inhibitors and Immune Checkpoint InhibitorsSemantic proximity Read

STING Promotes Breast Cancer Cell Survival by an Inflammatory-Independent Nuclear Pathway Enhancing the DNA Damage ResponseSemantic proximity Read

Efficacy and Mechanism of the Combination of PARP and CDK4/6 Inhibitors in the Treatment of Triple-negative Breast CancerSemantic proximity Read

Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiencySemantic proximity Read

A Phase I Study of ASTX727 plus Talazoparib in Patients with Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerSemantic proximity Read

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.Semantic proximity Read

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read